| Brown adipose tissue: a promising target to combat obesity. | |
| | |
MedLine Citation:
|
PMID: 20862392 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Obesity has now reached pandemic proportions leading to a collection of morbidities referred to as metabolic syndrome including insulin resistance, type 2 diabetes and cardiovascular disease. The expansion of adipose tissue is a direct cause of these comorbidities due to excessive accumulation of triglycerides within adipocytes, causing disruption of normal adipose function. There are two major types of adipose tissue, white and brown. The former stores energy as triglycerides within large droplets, whereas the latter catabolizes lipids to produce heat. A strategy to combat obesity-associated disorders, therefore, includes enhancement of brown adipose tissue activity by targeting the recently identified regulators of brown adipocyte development and function, including its master regulator, PRDM16. |
| | |
Authors:
|
Cecile Vernochet; Meghan E McDonald; Stephen R Farmer |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Review |
Journal Detail:
|
Title: Drug news & perspectives Volume: 23 ISSN: 0214-0934 ISO Abbreviation: Drug News Perspect. Publication Date: 2010 Sep |
Date Detail:
|
Created Date: 2010-09-23 Completed Date: 2011-01-10 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8809164 Medline TA: Drug News Perspect Country: United States |
Other Details:
|
Languages: eng Pagination: 409-17 Citation Subset: IM |
Copyright Information:
|
Copyright 2010 Prous Science, S.A.U. or its licensors. All rights reserved. |
Affiliation:
|
Department of Biochemistry, Boston University School of Medicine, Boston, Massachusetts 02118, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adipocytes, Brown
/
metabolism Adipose Tissue, Brown / metabolism* Animals Anti-Obesity Agents / pharmacology DNA-Binding Proteins / metabolism Drug Delivery Systems* Humans Metabolic Syndrome X / etiology Obesity / complications, drug therapy*, physiopathology Transcription Factors / metabolism Triglycerides / metabolism |
| Grant Support | |
ID/Acronym/Agency:
|
DK51586/DK/NIDDK NIH HHS; DK58825/DK/NIDDK NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Obesity Agents; 0/DNA-Binding Proteins; 0/PRDM16 protein, human; 0/Transcription Factors; 0/Triglycerides |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Erythropoiesis and iron sulfur cluster biogenesis.
Next Document: The significance of GPR119 agonists as a future treatment for type 2 diabetes.